ticarcillin (ticar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued.   NCATS

Chemistry

  • SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O
  • InChIKey: OHKOGUYZJXTSFX-KZFFXBSXSA-N
  • Mol. Mass: 384.427
  • ALogP: 0.55
  • ChEMBL Molecules:
    ticarcillin disodium  
    ticarcillin  
    None  
More Chemistry

Pharmacology

Combination drugs

( clavulanate (Augmentin), ticarcillin (ticar) )

Alternative names

(2s,5r,6r)-6-{[(2r)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | alpha-carboxy-3-thienylmethylpenicillin | brl-2288 | brl 28500 | brl-28500 | ticar | ticaracillin | ticarcilina | ticarcillin | ticarcillin-clavulanic acid | ticarcillin disodium | ticarcilline | ticarcillin monosodium | ticarcillin sodium | ticarcillin supplement | ticarcillinum | timentin

Organizations (15)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (5)


 

Intraabdominal Infections (approved 1976)

Reproductive Tract Infections (approved 1976)

Respiratory Tract Infections (approved 1976)

Sepsis (approved 1976)

Staphylococcal Skin Infections (approved 1976)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acne Vulgaris (Phase 3)

Cystic Fibrosis (Phase 4)

Diabetes Mellitus (Phase 2)

Infections (Phase 2)

Osteomyelitis (Early Phase 1)

Pelvic Infection (Phase 2)

Sepsis (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue